HK Stock MarketDetailed Quotes
02607 SH PHARMA
- 12.960
- +0.020+0.15%
Not Open Dec 23 16:08 CST
48.05BMarket Cap10.76P/E (TTM)
13.040High12.880Low1.74MVolume13.000Open12.940Pre Close22.55MTurnover0.19%Turnover Ratio11.56P/E (Static)3.71BShares14.70052wk High0.61P/B11.91BFloat Cap9.65252wk Low0.53Dividend TTM919.07MShs Float24.612Historical High0.440Dividend LFY1.24%Amplitude2.037Historical Low12.946Avg Price100Lot Size4.07%Div YieldTTM3.40%Div Yield LFY
SH PHARMA Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | 5.28%3.6B | ---- | -26.11%5.17B | ---- | -25.14%3.42B | ---- | 11.43%6.99B | ---- | 9.59%4.56B |
| Profit adjustment | ||||||||||
| Investment loss (gain) | ---- | -622.31%-342.02M | ---- | 73.90%-176M | ---- | 117.54%65.48M | ---- | 66.24%-674.26M | ---- | 78.97%-373.27M |
| Impairment and provisions: | ---- | 22.04%329.78M | ---- | 30.64%841.24M | ---- | 51.60%270.22M | ---- | 360.73%643.93M | ---- | -3.90%178.24M |
| -Other impairments and provisions | ---- | -12.80%293.26M | ---- | -10.40%279.96M | ---- | 54.49%336.32M | ---- | 46,192.99%312.46M | ---- | 8.25%217.69M |
| Revaluation surplus: | ---- | 41.94%-114.29M | ---- | -85.03%-404.73M | ---- | -675.23%-196.84M | ---- | -206.18%-218.74M | ---- | -171.34%-25.39M |
| Asset sale loss (gain): | ---- | -88.91%-139.31M | ---- | 93.57%-92.48M | ---- | 94.83%-73.75M | ---- | -2,368.58%-1.44B | ---- | -23,988.34%-1.43B |
| -Loss (gain) on sale of property, machinery and equipment | ---- | -88.91%-139.31M | ---- | 93.57%-92.48M | ---- | 94.83%-73.75M | ---- | -2,368.58%-1.44B | ---- | -23,988.34%-1.43B |
| Depreciation and amortization: | ---- | 5.97%1.25B | ---- | -1.36%2.38B | ---- | -0.99%1.18B | ---- | 3.88%2.41B | ---- | 1.44%1.19B |
| -Amortization of intangible assets | ---- | 5.22%198.8M | ---- | -2.14%380.6M | ---- | -5.75%188.94M | ---- | -8.69%388.91M | ---- | -2.18%200.45M |
| -Other depreciation and amortization | ---- | -13.56%85.95M | ---- | -1.46%192.33M | ---- | 16.79%99.43M | ---- | 4.44%195.19M | ---- | -4.81%85.14M |
| Financial expense | ---- | -4.95%915.72M | ---- | 9.47%1.86B | ---- | 14.92%963.41M | ---- | 8.49%1.7B | ---- | 17.71%838.33M |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | -8.38%1.34B | ---- | 67.61%-2.3B | ---- | 344.06%1.46B | ---- | -122.17%-7.11B | ---- | -227.79%-597.24M |
| Accounts receivable (increase)decrease | ---- | 25.37%-7.87B | ---- | 36.20%-6.43B | ---- | -30.21%-10.54B | ---- | -63.78%-10.08B | ---- | -20.30%-8.1B |
| Accounts payable increase (decrease) | ---- | -68.98%1.62B | ---- | -63.74%4.59B | ---- | 70.05%5.23B | ---- | 118.29%12.65B | ---- | -19.00%3.08B |
| Special items of business | ---- | 46.66%-68.55M | ---- | -55.73%-190.9M | ---- | -207.76%-128.52M | ---- | -170.75%-122.59M | ---- | -19.26%119.26M |
| Adjustment items of business operations | 20.87%2.78B | -66.96%583.86M | -108.65%-5.47B | 11.44%5.42B | 1,550.33%2.3B | 361.60%1.77B | -5.35%-2.62B | -0.45%4.87B | -105.43%-158.75M | -133.38%-675.44M |
| Net cash from operations | 20.87%2.78B | -68.55%515.3M | -108.65%-5.47B | 10.29%5.23B | 1,550.33%2.3B | 394.58%1.64B | -5.35%-2.62B | -6.28%4.74B | -105.43%-158.75M | -125.62%-556.18M |
| Cash flow from investment activities | ||||||||||
| Dividend received - investment | 36.03%971.32M | 122.44%701.77M | 4.18%120.9M | 11.68%982.75M | 23.04%714.04M | 20.77%315.48M | 38,581.96%116.05M | 16.96%879.94M | 14.62%580.31M | -13.61%261.21M |
| Sale of fixed assets | 8.20%159.08M | 46.92%138.69M | -95.96%815.73K | 11.73%179.15M | 34.59%147.03M | -9.00%94.4M | -67.91%20.22M | -16.01%160.34M | 50.90%109.24M | 95.21%103.74M |
| Purchase of fixed assets | 19.67%-1.84B | 7.35%-1.39B | -25.93%-871.62M | -10.64%-2.97B | -16.91%-2.28B | -46.70%-1.5B | -19.43%-692.12M | 34.81%-2.68B | -9.67%-1.95B | 10.89%-1.03B |
| Sale of subsidiaries | --12.36M | ---- | 105.03%11.51M | -99.53%500K | ---- | ---- | --5.62M | -6.07%106.8M | --3.54M | ---- |
| Acquisition of subsidiaries | 40.23%-93.69M | 44.69%-83.51M | 96.94%-4.03M | -323.42%-357.08M | 38.99%-156.75M | 20.64%-150.98M | 22.31%-132.08M | 92.69%-84.33M | 74.56%-256.95M | 77.69%-190.26M |
| Recovery of cash from investments | -25.97%17.45B | -9.52%11.35B | 8.92%10.05B | -8.54%26.88B | 10.25%23.58B | 15.83%12.54B | --9.23B | 1,058.86%29.39B | 1,021.22%21.39B | 1,100.77%10.83B |
| Cash on investment | 37.51%-15.86B | 41.37%-8.4B | 33.81%-7.1B | 31.01%-27.38B | 25.11%-25.38B | 33.01%-14.33B | ---10.73B | -1,160.67%-39.68B | -1,231.26%-33.89B | -1,852.30%-21.39B |
| Other items in the investment business | -219.59%-452.97M | -167.90%-280.57M | -580.74%-365.84M | 130.92%171.42M | 670.90%378.77M | 4,650.56%413.22M | 38.07%76.1M | 53.37%-554.36M | 95.44%-66.35M | 99.33%-9.08M |
| Net cash from investment operations | 111.93%357.98M | 177.76%2.03B | 187.44%1.84B | 80.02%-2.49B | 78.70%-3B | 77.10%-2.61B | -233.74%-2.11B | -107.35%-12.47B | -227.02%-14.08B | -257.63%-11.42B |
| Net cash before financing | 550.58%3.14B | 361.05%2.55B | 23.21%-3.63B | 135.44%2.74B | 95.11%-697.09M | 91.85%-976.23M | -51.53%-4.73B | -710.04%-7.73B | -930.42%-14.24B | -1,072.13%-11.97B |
| Cash flow from financing activities | ||||||||||
| New borrowing | -2.80%45.51B | 5.04%35.6B | -8.90%18.44B | 31.95%64.2B | 29.44%46.82B | 30.14%33.9B | 39.89%20.24B | 29.55%48.65B | 12.65%36.17B | 146.99%26.05B |
| Refund | -0.08%-50.54B | 6.68%-35.83B | 14.68%-17.41B | -20.95%-72.34B | -16.20%-50.5B | -26.19%-38.39B | -32.18%-20.41B | -14.54%-59.81B | 0.69%-43.46B | -63.21%-30.42B |
| Issuance of bonds | -25.00%9B | -50.00%6B | -50.00%3B | 0.03%15B | -20.00%12B | 33.32%12B | 0.04%6B | -21.06%14.99B | -6.23%15B | -9.98%9B |
| Dividends paid - financing | 21.23%-3.43B | 20.87%-1.1B | 32.40%-657.03M | -30.44%-4.92B | -38.72%-4.36B | -40.33%-1.39B | -97.72%-971.89M | -13.41%-3.77B | -8.23%-3.14B | -15.99%-993.22M |
| Absorb investment income | -94.84%18.32M | -98.81%3.74M | ---- | -97.49%354.28M | -97.46%355.19M | -97.75%314.36M | -98.88%156.81M | 8,239.98%14.12B | 13,400.69%14B | 25,097.43%14B |
| Other items of the financing business | 72.44%-420.16M | 29.36%-911.59M | 83.70%-113.39M | -0.48%-2.06B | -7.45%-1.52B | 1.38%-1.29B | 22.17%-695.79M | -629.79%-2.05B | -290.64%-1.42B | -288.42%-1.31B |
| Net cash from financing operations | -95.11%136.78M | -26.67%3.76B | -24.64%3.25B | -98.09%231.85M | -83.70%2.8B | -68.55%5.13B | -75.49%4.31B | 675.32%12.14B | 648.59%17.16B | 808.77%16.32B |
| Effect of rate | 62.41%-22.87M | -762.80%-8.19M | 161.07%7.74M | 55.14%-5.58M | -374.02%-60.84M | 4.02%-948.93K | -1,914.09%-12.67M | 75.28%-12.44M | 123.86%22.2M | 10.28%-988.68K |
| Net Cash | 56.17%3.28B | 51.89%6.31B | 8.37%-381.61M | -32.60%2.97B | -27.94%2.1B | -4.34%4.16B | -102.88%-416.49M | 621.13%4.41B | 220.26%2.91B | 461.21%4.34B |
| Begining period cash | 12.09%27.5B | 12.09%27.5B | 12.09%27.5B | 21.83%24.53B | 21.83%24.53B | 21.83%24.53B | 21.83%24.53B | 2.87%20.14B | 2.87%20.14B | 2.87%20.14B |
| Cash at the end | 15.74%30.75B | 17.83%33.8B | 12.53%27.13B | 12.09%27.5B | 15.17%26.57B | 17.19%28.69B | -30.36%24.1B | 21.83%24.53B | 13.14%23.07B | 20.30%24.48B |
| Cash balance analysis | ||||||||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
HK
Overall
Symbol
Price
% Chg
No Data
